Best practice & research. Clinical endocrinology & metabolism最新文献_第6页

Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks 比较成人生长激素缺乏症每日和长效生长激素制剂的治疗:挑战性问题，益处和风险

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-12-01 DOI: 10.1016/j.beem.2023.101788

Charlotte Höybye (Senior physician and Associate Professor)

{"title":"Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks","authors":"Charlotte Höybye (Senior physician and Associate Professor)","doi":"10.1016/j.beem.2023.101788","DOIUrl":"10.1016/j.beem.2023.101788","url":null,"abstract":"<div>Daily administration of growth hormone (GH) treatment has been in clinical use for treatment for GH deficiency (GHD) in adults for more than 30 years. Numerous studies have demonstrated evidence that GH treatment improves body composition, cardiovascular risk factors and quality of life with few side effects. Less frequent GH injections are hypothesized to improve adherence and several long-acting GH (LAGH) formulations have been developed and a few have been approved and marketed. Different pharmacological modifications have been applied and the pharmacokinetics and pharmacodynamics of LAGH are different to each other and to those of daily injections and require different dosing and monitoring specific for each LAGH. Studies have shown improved adherence with LAGH, and short-term efficacy and side effects are comparable between daily GH injections and LAGHs. Long-term treatment with daily GH injections is effective and safe, while long-term studies for LAGHs are awaited. In this review challenges, benefits, and risks of treatment with daily and long-acting GH preparations will be compared.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 6","pages":"Article 101788"},"PeriodicalIF":7.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521690X23000623/pdfft?md5=7b48deb6c2e46b5d1285d75553de0c5f&pid=1-s2.0-S1521690X23000623-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk 生长激素缺乏成人长期使用每日和长效生长激素对癌症风险的安全性

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-12-01 DOI: 10.1016/j.beem.2023.101817

Cesar Luiz Boguszewski (Full Professor of Endocrinology)

引用次数: 0

Growth hormone replacement in adults with cured acromegaly: Efficacy and safety 生长激素替代治疗成人肢端肥大症:疗效和安全性

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-12-01 DOI: 10.1016/j.beem.2023.101790

Nicholas A. Tritos (Associate Professor of Medicine)

{"title":"Growth hormone replacement in adults with cured acromegaly: Efficacy and safety","authors":"Nicholas A. Tritos (Associate Professor of Medicine)","doi":"10.1016/j.beem.2023.101790","DOIUrl":"10.1016/j.beem.2023.101790","url":null,"abstract":"<div>Between 2% and 60% of patients with cured acromegaly may eventually develop growth hormone deficiency. In adults, growth hormone deficiency is associated with abnormal body composition, decreased exercise capacity and quality of life, dyslipidemia, insulin resistance and increased cardiovascular risk. Similar to patients with other sellar lesions, the diagnosis of growth hormone deficiency in adults with cured acromegaly generally requires stimulation testing, with the exception of patients with very low serum insulin-like growth factor I levels and multiple additional pituitary hormone deficiencies. In adults with cured acromegaly, growth hormone replacement may have beneficial effects on body adiposity, muscle endurance, serum lipids and quality of life. Growth hormone replacement is generally well-tolerated. Arthralgias, edema, carpal tunnel syndrome and hyperglycemia may occur in patients with cured acromegaly, as is true of patients with growth hormone deficiency of other etiologies. However, there is evidence of increased cardiovascular risk in some studies of growth hormone replacement in adults with cured acromegaly. More studies are needed to fully establish the beneficial effects and elucidate the risks of growth hormone replacement in adults with cured acromegaly. Until then, growth hormone replacement can be considered in these patients on a case-by-case basis.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 6","pages":"Article 101790"},"PeriodicalIF":7.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9641302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates? 生长激素缺乏症成人死亡率的荟萃分析：生长激素替代疗法真的能提高死亡率吗？

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-12-01 DOI: 10.1016/j.beem.2023.101835

Christa C. van Bunderen (Assistant Professor in Endocrinology) , Daniel S. Olsson (Professor (adj) in Endocrinology)

{"title":"Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates?","authors":"Christa C. van Bunderen (Assistant Professor in Endocrinology) , Daniel S. Olsson (Professor (adj) in Endocrinology)","doi":"10.1016/j.beem.2023.101835","DOIUrl":"10.1016/j.beem.2023.101835","url":null,"abstract":"<div>Growth hormone (GH) deficiency (GHD) is one of the most prevalent deficiencies in patients with hypopituitarism and several cohort studies have demonstrated an increased mortality risk in hypopituitary patients with a presumed GHD. The cause of the excess mortality is most likely multifactorial, including the etiology of the hypopituitarism, non-physiological replacement therapies (mostly glucocorticoid), tumor treatment and its side effects as well as untreated GHD. Several years later, other cohort studies that investigated life expectancy in patients with hypopituitarism on GH replacement therapy (GHRT) that showed a normalized mortality. By comparison of the distribution of characteristics of interest between cohorts, we discuss the existing literature to answer the following question: does growth hormone replacement really improve mortality rates in adult patients with hypopituitarism and GHD? We also conducted a meta-analysis of these studies. Since the literature suffers from selection and time bias (improvement of tumor management and other pituitary hormone replacement therapies), there is no high-quality evidence that replacement therapy for GHD really improves mortality. However, the available data does suggest that GHRT plays a significant part in the normalization of the mortality in patients with hypopituitarism.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 6","pages":"Article 101835"},"PeriodicalIF":7.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521690X23001094/pdfft?md5=88af5ce15f3f6ff3dba0ffef74dc4876&pid=1-s2.0-S1521690X23001094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pathophysiology of hypophosphatemia 低磷血症的病理生理学

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-11-30 DOI: 10.1016/j.beem.2023.101851

Nobuaki Ito (Project Lecturer in Endocrinology) , Naoko Hidaka (Senior Endocrinologist) , Hajime Kato (Assistant Professor in Endocrinology)

{"title":"The pathophysiology of hypophosphatemia","authors":"Nobuaki Ito (Project Lecturer in Endocrinology) , Naoko Hidaka (Senior Endocrinologist) , Hajime Kato (Assistant Professor in Endocrinology)","doi":"10.1016/j.beem.2023.101851","DOIUrl":"10.1016/j.beem.2023.101851","url":null,"abstract":"<div>After identification of fibroblast growth factor (FGF) 23 as the pivotal regulator of chronic serum inorganic phosphate (Pi) levels, the etiology of disorders causing hypophosphatemic rickets/osteomalacia has been clarified, and measurement of intact FGF23 serves as a potent tool for differential diagnosis of chronic hypophosphatemia. Additionally, measurement of bone-specific alkaline phosphatase (BAP) is recommended to differentiate acute and subacute hypophosphatemia from chronic hypophosphatemia. This article divides the etiology of chronic hypophosphatemia into 4 groups: A. FGF23 related, B. primary tubular dysfunction, C. disturbance of vitamin D metabolism, and D. parathyroid hormone 1 receptor (PTH1R) mediated. Each group is further divided into its inherited form and acquired form. Topics for each group are described, including “ectopic FGF23 syndrome,” “alcohol consumption-induced FGF23-related hypophosphatemia,” “anti-mitochondrial antibody associated hypophosphatemia,” and “vitamin D-dependent rickets type 3.” Finally, a flowchart for differential diagnosis of chronic hypophosphatemia is introduced.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"38 2","pages":"Article 101851"},"PeriodicalIF":7.4,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138506149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inherited fibroblast growth factor 23 excess 遗传性成纤维细胞生长因子23过量。

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-11-28 DOI: 10.1016/j.beem.2023.101844

Kripa Elizabeth Cherian (Associate Professor), Thomas Vizhalil Paul (Professor)

{"title":"Inherited fibroblast growth factor 23 excess","authors":"Kripa Elizabeth Cherian (Associate Professor), Thomas Vizhalil Paul (Professor)","doi":"10.1016/j.beem.2023.101844","DOIUrl":"10.1016/j.beem.2023.101844","url":null,"abstract":"<div>Syndromes of inherited fibroblast growth factor 23 (FGF-23) excess encompass a wide spectrum that includes X-linked hypophosphataemia (XLH), autosomal dominant and recessive forms of rickets as well as various syndromic conditions namely fibrous dysplasia/McCune Albright syndrome, osteoglophonic dysplasia, Jansen’s chondrodysplasia and cutaneous skeletal hypophosphataemia syndrome. A careful attention to patient symptomatology, family history and clinical features, supported by appropriate laboratory tests will help in making a diagnosis. A genetic screen may be done to confirm the diagnosis. While phosphate supplements and calcitriol continue to be the cornerstone of treatment, in recent times burosumab, the monoclonal antibody against FGF-23 has been approved for the treatment of children and adults with XLH. While health-related outcomes may be improved by ensuring adherence and compliance to prescribed treatment with a smooth transition to adult care, bony deformities may persist in some, and this would warrant surgical correction.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"38 2","pages":"Article 101844"},"PeriodicalIF":7.4,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review 遗传性非fgf23介导的磷酸化疾病:以肾脏为中心的综述。

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-11-25 DOI: 10.1016/j.beem.2023.101843

Emma Walker (Paediatrics trainee) , Wesley Hayes (Consultant Paediatric Nephrologist) , Detlef Bockenhauer (Professor and Consultant Paediatric Nephrologist)

{"title":"Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review","authors":"Emma Walker (Paediatrics trainee) , Wesley Hayes (Consultant Paediatric Nephrologist) , Detlef Bockenhauer (Professor and Consultant Paediatric Nephrologist)","doi":"10.1016/j.beem.2023.101843","DOIUrl":"10.1016/j.beem.2023.101843","url":null,"abstract":"<div>Phosphate is freely filtered by the glomerulus and reabsorbed exclusively in the proximal tubule by two key transporters, NaPiIIA and NaPiIIC, encoded by SLC34A1 and SLC34A3, respectively. Regulation of these transporters occurs primarily through the hormone FGF23 and, to a lesser degree, PTH. Consequently, inherited non-FGF23 mediated phosphaturic disorders are due to generalised proximal tubular dysfunction, loss-of-function variants in SLC34A1 or SLC34A3 or excess PTH signalling. The corresponding disorders are Renal Fanconi Syndrome, Infantile Hypercalcaemia type 2, Hereditary Hypophosphataemic Rickets with Hypercalciuria and Familial Hyperparathyroidism. Several inherited forms of Fanconi renotubular syndrome (FRTS) have also been described with the underlying genes encoding for GATM, EHHADH, HNF4A and NDUFAF6. Here, we will review their pathophysiology, clinical manifestations and the implications for treatment from a kidney-centric perspective, focussing on those disorders caused by dysfunction of renal phosphate transporters. Moreover, we will highlight specific genetic aspects, as the availability of large population genetic databases has raised doubts about some of the originally proposed gene-disease associations concerning phosphate transporters or their associated proteins.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"38 2","pages":"Article 101843"},"PeriodicalIF":7.4,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia 后天性磷酸尿症：超越肿瘤诱发的骨软化症

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-11-10 DOI: 10.1016/j.beem.2023.101839

Sayali B. Thakare (Nephrologist), Tukaram E. Jamale (Nephrologist) , Saba S. Memon (Endocrinologist)

引用次数: 0

Phosphate: An underrated component of primary hyperparathyroidism 磷酸盐：原发性甲状旁腺功能亢进的一种被低估的成分。

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-10-31 DOI: 10.1016/j.beem.2023.101837

Sanjay Kumar Bhadada , Jayaditya Ghosh , Rimesh Pal , Soham Mukherjee

{"title":"Phosphate: An underrated component of primary hyperparathyroidism","authors":"Sanjay Kumar Bhadada , Jayaditya Ghosh , Rimesh Pal , Soham Mukherjee","doi":"10.1016/j.beem.2023.101837","DOIUrl":"10.1016/j.beem.2023.101837","url":null,"abstract":"<div>Primary hyperparathyroidism (PHPT) is a systemic disease that affects all the systems of the body, specifically the bones and the kidneys. Its main action is on calcium homeostasis. It tries to preserve the body’s calcium level at the cost of phosphate. The criteria for surgery in asymptomatic PHPT patients revolve around raised serum calcium levels, renal dysfunction or nephrolithiasis, and bone health. It does not take into account the serum phosphate levels. Depending on the serum level, Hypophosphatemia is divided into mild, moderate, and severe categories. In PHPT, several studies have suggested that asymptomatic PHPT patients with moderate hypophosphatemia may warrant surgical intervention. Treatment of hypophosphatemia in PHPT is based upon the degree of hypophosphatemia, and treatment is given according to that oral or intravenous route; after surgical and medical treatment of PHPT, phosphate levels gradually normalized. But even after these considerations, phosphate levels in PHPT are not given much importance.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"38 2","pages":"Article 101837"},"PeriodicalIF":7.4,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor-induced osteomalacia: An overview 肿瘤引起的骨软化：综述。

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-10-20 DOI: 10.1016/j.beem.2023.101834

Swati Sachin Jadhav (Consultant Endocrine Oncologist) , Ravikumar Shah (Consultant Endocrinologist) , Virendra Patil (Associate Professor)

{"title":"Tumor-induced osteomalacia: An overview","authors":"Swati Sachin Jadhav (Consultant Endocrine Oncologist) , Ravikumar Shah (Consultant Endocrinologist) , Virendra Patil (Associate Professor)","doi":"10.1016/j.beem.2023.101834","DOIUrl":"10.1016/j.beem.2023.101834","url":null,"abstract":"<div>Tumor-induced osteomalacia (TIO) is rare paraneoplastic syndrome of hypophosphatemic osteomalacia, caused by phosphaturic factors secreted by small mesenchymal origin tumors with distinct pathological features, called ‘phosphaturic mesenchymal tumors’. FGF23 is the most well-characterized of the phosphaturic factors. Tumors are often small and located anywhere in the body from head to toe, which makes the localisation challenging. Functional imaging by somatostatin receptor-based PET imaging is the first line investigation, which should be followed with CT or MRI based anatomical imaging. Once localised, complete surgical excision is the treatment of choice, which brings dramatic resolution of symptoms. Medical management in the form of phosphate and active vitamin D supplements is given as a bridge to surgical management or in inoperable/non-localised patients. This review provides an overview of the epidemiology, pathophysiology, pathology, clinical features, diagnosis, and treatment of TIO, including the recent advances and directions for future research in this field.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"38 2","pages":"Article 101834"},"PeriodicalIF":7.4,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0